{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:36Z","timestamp":1793286216992,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Carbamazepine and oxcarbazepine are potent modulators of metabolic enzymes. Hence, potential drug-drug interactions (DDIs) may occur between these 2 drugs and antiretrovirals. Here, we aimed to assess the relevance of these drug-drug interactions in real-life clinical settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients treated concomitantly with carbamazepine or oxcarbazepine and antiretrovirals for at least 3 months were considered. Data on therapeutic drug monitoring (TDM) of both antiepileptic and antiretrovirals as trough concentrations were collected. HIV-infected patients not concomitantly treated with antiepileptic drugs and who underwent TDM for antiretrovirals in the previous 2 years were considered as controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eleven HIV-positive patients prescribed carbamazepine or oxcarbazepine were identified. All the TDM evaluations for carbamazepine and oxcarbazepine that resulted were within the therapeutic ranges. TDM results of darunavir measured in these patients were comparable with values usually measured in the control group. Conversely, the trough concentrations for atazanavir and dolutegravir demonstrated significantly lower values when compared with values usually measured in HIV-infected patients not treated with antiepileptic drugs (190 \u00b1 91 versus 546 \u00b1 380 ng\/mL; \u221265%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001; 191 \u00b1 78 versus 1096 \u00b1 510 ng\/mL; \u221283%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Co-administration of carbamazepine or oxcarbazepine with atazanavir or dolutegravir should be avoided owing to the potential risk of virological failure; in case of these 2 drugs, the adoption of TDM is strongly advisable, eventually combining with increased antiretroviral doses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000715","type":"journal-article","created":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T23:47:52Z","timestamp":1574034472000},"page":"330-334","source":"Crossref","is-referenced-by-count":11,"title":["Drug-Drug Interactions Between Antiretrovirals and Carbamazepine\/Oxcarbazepine: A Real-Life Investigation"],"prefix":"10.1097","volume":"42","author":[{"given":"Dario","family":"Cattaneo","sequence":"first","affiliation":[{"name":"Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital;"},{"name":"Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldelli","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cozzi","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fusi","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Atzori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[{"name":"Unit of Clinical Microbiology, Virology and Diagnosis of Bioemergency, ASST Fatebenefratelli Sacco University Hospital, Milan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Filice","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[{"name":"Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital;"},{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006453.pub2","article-title":"Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures","author":"Koch","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1461145704004651","article-title":"A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder","volume":"7","author":"Hirschfeld","year":"2004","journal-title":"Int J Neuropsychopharmacol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.yebeh.2004.07.004","article-title":"What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?","volume":"5","author":"Schmidt","year":"2004","journal-title":"Epilepsy Behav."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/00498254.2015.1118774","article-title":"Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells","volume":"46","author":"Sugiyama","year":"2016","journal-title":"Xenobiotica."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/096032719801701204","article-title":"Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta","volume":"17","author":"Myllynen","year":"1998","journal-title":"Hum Exp Toxicol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"40","DOI":"10.24875\/AIDSRev.19000035","article-title":"Management of polypharmacy and drug-drug interactions in HIV patients: a 2-year experience of a multidisciplinary outpatient clinic","volume":"21","author":"Gervasoni","year":"2019","journal-title":"AIDS Rev."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpha.2016.05.008","article-title":"Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients","volume":"6","author":"Charbe","year":"2016","journal-title":"J Pharm Anal."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/FTD.0000000000000290","article-title":"Development and validation of a chromatographic ultraviolet method for the simultaneous quantification of dolutegravir and rilpivirine in human plasma","volume":"38","author":"Cozzi","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkr498","article-title":"Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects","volume":"67","author":"Cattaneo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1128\/AAC.00942-12","article-title":"Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing","volume":"56","author":"Cattaneo","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"e0123670","DOI":"10.1371\/journal.pone.0123670","article-title":"Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?","volume":"10","author":"Gervasoni","year":"2015","journal-title":"PLoS One."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1097\/QAD.0000000000000440","article-title":"Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint","volume":"28","author":"Cattaneo","year":"2014","journal-title":"AIDS."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.ftd.0000186914.32038.a0","article-title":"Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations","volume":"27","author":"Gervasini","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","article-title":"Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review","volume":"42","author":"Cattaneo","year":"2020","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:38:11Z","timestamp":1692052691000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000715","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}